COMP <GO>
RARE vs NUVB // ENTERPRISE SCALE & MARKET CAP
Ultragenyx Pharmaceutical Inc. (NASDAQ) VS. Nuvation Bio Inc. (Class A) (NYSE) • 15-METRIC TALLY: RARE 1
— NUVB 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: NUVB
LAST: $16.78 (-2.44%) • MKT CAP: $1.65B
market-cap
$1.65B
LAST: $4.77 (+3.92%) • MKT CAP: $1.67B
market-cap
$1.67B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RARE VS. NUVB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RARE | NUVB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.35% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 180.00% | -159.80 | NUVB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.76 | -0.56 | NUVB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | NUVB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 42.2 | +7.58 | RARE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.65B | $1.67B | -$20.5M | NUVB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RARE REV | NUVB REV | RARE GROSS % | NUVB GROSS % | RARE FCF | NUVB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $673.0M | $62.9M | — | — | -$472.0M | -$173.4M |
| FY 2024 | $560.0M | $7.9M | — | 10.1% | -$421.0M | -$130.4M |
| FY 2023 | $434.0M | $0 | — | — | -$475.0M | -$68.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RARE // BETA —
NUVB // BETA —